



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

1634
#7
RECEIVED

6-27-02
attachment
JUN 24 2002


TECH CENTER 1600/2900

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 13, 2002

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 13, 2002	
Date	
	Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/021,753 entitled "METHODS AND COMPOSITIONS RELATING TO FORTILIN, AN ANTI-APOPTOTIC MOLECULE, AND MODULATORS OF FORTILIN" by Ken Fujise and Edward T.H. Yeh*
Our Reference: UTSN:251US


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C16-C18).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110495/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Gina N. Shishima
Reg. No. 45,104

GNS/cmb
Encl.: as noted

25176842.1

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Ken Fujise
Edward T.H. Yeh

Serial No.: 10/021,753

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS
RELATING TO FORTILIN, AN ANTI-
APOPTOTIC MOLECULE, AND
MODULATORS OF FORTILIN



Group Art Unit: 1632

Examiner: Unknown


Atty. Dkt. No.: UTSH:251US

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 13, 2002	
Date	Gina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110495/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 13, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSH:251USSerial No.
10/021,753

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Ken Fujise
Edward T.H. YehFiling Date:
October 30, 2001Group:
1632U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

JUN 24 2002

RECEIVED

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Bhisutthibhan <i>et al.</i> , "The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin," <i>J. Biol. Chem.</i> , 273(26):16192-16198, 1998.
	C17	Garrigos <i>et al.</i> , "Detection of Ca ²⁺ -binding proteins by electrophoretic migration in the presence of Ca ²⁺ combined with ⁴⁵ Ca ²⁺ overlay of protein blots," <i>Analytical Biochemistry</i> , 194:82-88, 1991.
	C18	Yoon <i>et al.</i> , "Identification of the self-interaction of rat TCTP/IgE-dependent histamine-releasing factor using yeast two-hybrid system," <i>Archives of Biochem. And Biophys.</i> , 384(2):379-382, 2000.

COPY OF PAPERS
ORIGINALLY FILED

25176822.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)